BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27219881)

  • 1. Osteoporosis Management in a Real Clinical Setting: Heterogeneity in Intervention Approach and Discrepancy in Treatment Rates when Compared with the NOGG and NOF Guidelines.
    Kyriakos G; Vidal-Casariesgo A; Quiles-Sánchez LV; Urosa-Maggi JA; Calleja-Fernández A; Hernández-Moreno A; Ballesteros-Pomar MD; Cano-Rodriguez I
    Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):466-473. PubMed ID: 27219881
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of the NOGG and NOF Guidelines on the Indication of Bone Mineral Density in Routine Clinical Practice.
    Kyriakos G; Vidal-Casariego A; Fernández-Martínez MN; Blanco-Suárez MD; Ballesteros-Pomar MD; Cano-Rodríguez I
    J Clin Densitom; 2015; 18(4):533-8. PubMed ID: 26343823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study between the implementation of the FRIDEX calibration and the NOGG guideline in the management of osteoporosis in routine clinical practice.
    Kyriakos G; Vidal-Casariego A; Quiles-Sánchez LV; Calleja-Fernández A; Ávila-Turcios D; Urosa-Maggi JA; Ballesteros-Pomar MD; Cano-Rodríguez I
    Reumatol Clin; 2017; 13(5):258-263. PubMed ID: 27373582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparate outcomes from applying U.K. and U.S. osteoporosis treatment guidelines.
    Bolland MJ; Grey A
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1856-60. PubMed ID: 20147581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of UK National Guidelines based on FRAX®--comparison with current clinical practice.
    Crabtree NJ; Bebbington NA; Chapman DM; Wahid YS; Ayuk J; Boivin CM; Cooper MS; Gittoes NJ;
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):452-6. PubMed ID: 20626412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the NOF and NOGG guidelines for spinal radiographic examination in postmenopausal Chinese women.
    Chen R; Liu S; Huang M; Ding N; Wang Q; Xie Z; Liu H; Sheng Z; Ou Y
    Arch Osteoporos; 2021 Jan; 16(1):5. PubMed ID: 33399996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of clinical risk factors for osteoporosis and applicability of the FRAX tool in Joinville City, Southern Brazil.
    Silva DMW; Borba VZC; Kanis JA
    Arch Osteoporos; 2017 Dec; 12(1):111. PubMed ID: 29224172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting fracture risk in osteoporosis: the use of fracture prediction tools in an osteoporosis clinic population.
    Aw D; Thain J; Ali A; Aung T; Chua WM; Sahota O; Weerasuriya N; Marshall L; Kearney F; Masud T
    Postgrad Med J; 2016 May; 92(1087):267-70. PubMed ID: 26792635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, Spain.
    Hurtado I; Sanfélix-Gimeno G; Baixauli-Pérez C; Peiró S; Sanfélix-Genovés J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):142-50. PubMed ID: 24384018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of osteoporosis guideline has important implications for the treatment decision in elderly women referred to a fall clinic.
    Thomsen K; Ryg J; Matzen L; Hermann AP; Masud T
    Dan Med J; 2014 Dec; 61(12):A4980. PubMed ID: 25441734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting.
    Carter M
    J Clin Densitom; 2019; 22(1):25-30. PubMed ID: 29729949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of strategies for setting intervention thresholds for Chinese postmenopausal women using the FRAX model.
    Liu SY; Huang M; Chen R; Ding N; Liu H; Xie ZJ; Sheng ZF; Luo BH; Ou YN
    Endocrine; 2019 Jul; 65(1):200-206. PubMed ID: 31111436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FRAX-based osteoporosis intervention using real world data.
    Goldshtein I; Ish-Shalom S; Leshno M
    Bone; 2017 Oct; 103():318-324. PubMed ID: 28778597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical decision support system for the management of osteoporosis compared to NOGG guidelines and an osteology specialist: a validation pilot study.
    Gudmundsson HT; Hansen KE; Halldorsson BV; Ludviksson BR; Gudbjornsson B
    BMC Med Inform Decis Mak; 2019 Feb; 19(1):27. PubMed ID: 30709348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines : A report for the National Osteoporosis Guideline Group (NOGG).
    Kanis JA; Johansson H; Harvey NC; Lorentzon M; Liu E; Vandenput L; McCloskey EV
    Osteoporos Int; 2021 Oct; 32(10):1951-1960. PubMed ID: 33813622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmenopausal osteoporosis risk management in primary care: how well does it adhere to national practice guidelines?
    Wei GS; Jackson JL; O'Malley PG
    J Am Med Womens Assoc (1972); 2003; 58(2):99-104. PubMed ID: 12744423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of applying the NOF, NOGG and Taiwanese guidelines to a cohort of Chinese early postmenopausal women.
    Cheung E; Kung AW; Tan KC
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):200-7. PubMed ID: 24010883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Usefulness of FRAX tool for the management of osteoporosis in the Spanish female population].
    Azagra Ledesma R; Prieto-Alhambra D; Encabo Duró G; Casado Burgos E; Aguyé Batista A; Díez-Pérez A;
    Med Clin (Barc); 2011 May; 136(14):613-9. PubMed ID: 21349558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing osteoporosis with FRAX® in Australia: proposed new treatment thresholds from the 45&Up Study cohort.
    Chen JS; Simpson JM; Blyth FM; March LM
    Bone; 2014 Dec; 69():148-53. PubMed ID: 25263521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of FRAX as a determinant for risk-based osteoporosis screening may decrease unnecessary testing while improving the odds of identifying treatment candidates.
    Edwards FD; Grover ML; Cook CB; Chang YH
    Womens Health Issues; 2014; 24(6):629-34. PubMed ID: 25128036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.